vs
ANI PHARMACEUTICALS INC（ANIP）とVERRA MOBILITY Corp（VRRM）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $223.6M、VERRA MOBILITY Corpの約1.1倍）。VERRA MOBILITY Corpの純利益率が高く（12.0% vs 11.1%、差は0.8%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 0.1%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $9.6M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 0.3%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Verra Mobility Corpは世界有数のスマートモビリティ技術ソリューションプロバイダーで、料金管理、駐車・交通規制執行、コネクテッドカーサービス、車両隊管理ツールを提供しています。主な顧客は政府交通機関、レンタカー事業者、商用車隊所有者、自動車業界パートナーで、事業は北米、欧州、アジア太平洋地域に展開しています。
ANIP vs VRRM — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $223.6M |
| 純利益 | $27.5M | $26.7M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 23.2% |
| 純利益率 | 11.1% | 12.0% |
| 売上前年比 | 29.6% | 0.1% |
| 純利益前年比 | 367.5% | -17.3% |
| EPS（希薄化後） | $1.14 | $0.17 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $223.6M | ||
| Q4 25 | $247.1M | $257.9M | ||
| Q3 25 | $227.8M | $261.9M | ||
| Q2 25 | $211.4M | $236.0M | ||
| Q1 25 | $197.1M | $223.3M | ||
| Q4 24 | $190.6M | $221.5M | ||
| Q3 24 | $148.3M | $225.6M | ||
| Q2 24 | $138.0M | $222.4M |
| Q1 26 | — | $26.7M | ||
| Q4 25 | $27.5M | $18.9M | ||
| Q3 25 | $26.6M | $46.8M | ||
| Q2 25 | $8.5M | $38.6M | ||
| Q1 25 | $15.7M | $32.3M | ||
| Q4 24 | $-10.3M | $-66.7M | ||
| Q3 24 | $-24.2M | $34.7M | ||
| Q2 24 | $-2.3M | $34.2M |
| Q1 26 | — | 23.2% | ||
| Q4 25 | 14.1% | 16.7% | ||
| Q3 25 | 15.9% | 28.6% | ||
| Q2 25 | 6.6% | 26.8% | ||
| Q1 25 | 13.3% | 25.7% | ||
| Q4 24 | -2.3% | -19.6% | ||
| Q3 24 | -13.8% | 28.3% | ||
| Q2 24 | 3.7% | 27.5% |
| Q1 26 | — | 12.0% | ||
| Q4 25 | 11.1% | 7.3% | ||
| Q3 25 | 11.7% | 17.9% | ||
| Q2 25 | 4.0% | 16.3% | ||
| Q1 25 | 8.0% | 14.5% | ||
| Q4 24 | -5.4% | -30.1% | ||
| Q3 24 | -16.3% | 15.4% | ||
| Q2 24 | -1.7% | 15.4% |
| Q1 26 | — | $0.17 | ||
| Q4 25 | $1.14 | $0.12 | ||
| Q3 25 | $1.13 | $0.29 | ||
| Q2 25 | $0.36 | $0.24 | ||
| Q1 25 | $0.69 | $0.20 | ||
| Q4 24 | $-0.45 | $-0.39 | ||
| Q3 24 | $-1.27 | $0.21 | ||
| Q2 24 | $-0.14 | $0.20 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $46.9M |
| 総負債低いほど良い | — | $34.1M |
| 株主資本純資産 | $540.7M | $272.0M |
| 総資産 | $1.4B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.13× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $46.9M | ||
| Q4 25 | $285.6M | $65.3M | ||
| Q3 25 | $262.6M | $196.1M | ||
| Q2 25 | $217.8M | $147.7M | ||
| Q1 25 | $149.8M | $108.5M | ||
| Q4 24 | $144.9M | $77.6M | ||
| Q3 24 | $145.0M | $206.1M | ||
| Q2 24 | $240.1M | $122.0M |
| Q1 26 | — | $34.1M | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B |
| Q1 26 | — | $272.0M | ||
| Q4 25 | $540.7M | $293.0M | ||
| Q3 25 | $505.8M | $403.1M | ||
| Q2 25 | $436.8M | $352.1M | ||
| Q1 25 | $418.6M | $299.6M | ||
| Q4 24 | $403.7M | $265.1M | ||
| Q3 24 | $405.9M | $486.5M | ||
| Q2 24 | $455.8M | $438.6M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.9B | ||
| Q2 24 | $920.8M | $1.8B |
| Q1 26 | — | 0.13× | ||
| Q4 25 | — | 3.51× | ||
| Q3 25 | — | 2.55× | ||
| Q2 25 | — | 2.93× | ||
| Q1 25 | — | 3.45× | ||
| Q4 24 | — | 3.90× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 2.36× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $40.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $9.6M |
| FCFマージンFCF / 売上 | 11.8% | 4.3% |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.53× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $104.6M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $40.8M | ||
| Q4 25 | $30.4M | $40.0M | ||
| Q3 25 | $44.1M | $77.7M | ||
| Q2 25 | $75.8M | $75.1M | ||
| Q1 25 | $35.0M | $63.0M | ||
| Q4 24 | $15.9M | $40.5M | ||
| Q3 24 | $12.5M | $108.8M | ||
| Q2 24 | $17.4M | $40.0M |
| Q1 26 | — | $9.6M | ||
| Q4 25 | $29.1M | $5.7M | ||
| Q3 25 | $38.0M | $49.0M | ||
| Q2 25 | $71.8M | $40.3M | ||
| Q1 25 | $32.5M | $41.7M | ||
| Q4 24 | $13.5M | $21.6M | ||
| Q3 24 | $7.7M | $85.1M | ||
| Q2 24 | $13.0M | $26.0M |
| Q1 26 | — | 4.3% | ||
| Q4 25 | 11.8% | 2.2% | ||
| Q3 25 | 16.7% | 18.7% | ||
| Q2 25 | 34.0% | 17.1% | ||
| Q1 25 | 16.5% | 18.7% | ||
| Q4 24 | 7.1% | 9.8% | ||
| Q3 24 | 5.2% | 37.7% | ||
| Q2 24 | 9.4% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 13.3% | ||
| Q3 25 | 2.7% | 11.0% | ||
| Q2 25 | 1.9% | 14.8% | ||
| Q1 25 | 1.3% | 9.5% | ||
| Q4 24 | 1.3% | 8.5% | ||
| Q3 24 | 3.2% | 10.5% | ||
| Q2 24 | 3.2% | 6.3% |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 1.10× | 2.12× | ||
| Q3 25 | 1.66× | 1.66× | ||
| Q2 25 | 8.87× | 1.95× | ||
| Q1 25 | 2.23× | 1.95× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.13× | ||
| Q2 24 | — | 1.17× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
VRRM
| Government Solutions segment generated total | $105.3M | 47% |
| Commercial Services segment generated total | $97.8M | 44% |
| Parking Solutions segment generated total | $20.4M | 9% |
